<DOC>
	<DOCNO>NCT01138501</DOCNO>
	<brief_summary>This trial conduct Asia , Europe , North South America . The aim clinical trial investigate safety efficacy turoctocog alfa ( recombinant factor VIII , rFVIII ( N8 ) ) male previously treat paediatric subject haemophilia A .</brief_summary>
	<brief_title>Safety Efficacy Turoctocog Alfa Previously Treated Male Children With Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male patient severe ( baseline FVIII le equal 1 % ) haemophilia A Age 12 year weight least 11 kg Surgery plan occur trial participation ( exception port placement , dental extraction , minor , uncomplicated emergent procedure ) Congenital acquire coagulation disorder haemophilia A Any history FVIII inhibitor ( great equal 0.6 BU/mL )</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>